Abstract:While our understanding of the developmental biology of the skeleton, like that of virtually every other subject in biology, has been transformed by recent advances in human and mouse genetics, we still know very little, in molecular and genetic terms, about skeletal physiology. Thus, among the many questions that are largely unexplained are the following: why is osteoporosis mainly a women's disease? How is bone mass maintained nearly constant between the end of puberty and the arrest of gonadal functions? Molecular genetics has emerged as a powerful tool to study previously unexplored aspects of the physiology of the skeleton. Among mammals, mice are the most promising animals for this experimental work. This has been previously demonstrated e.g. through the tremendous impact of the different osteopetrotic models on our molecular understanding of osteoclastic bone resorption. Until recently the only way of studying bone loss situations and osteoporosis in mice was by using ovariectomy with all its limitations. Today, however, we have access to more sophisticated osteoporotic mouse-models from four different origins: Transgenic mice (HSV-TK), knock-out mice (OPG), inbred-strains (SAMP6), and through physiological modulation (icv application). These new models have already taught us several important lessons. The first is, that bone remodeling is more than just an autocrine/paracrine process. Multiple experimental evidence has demonstrated that the latter regulation exists, but genetics prove that there is no functional cross-control between resorption and formation. The second lesson is, that remodeling is, at least in part, subject to central regulation. Thus, osteoporosis is partly a central or hypothalamic disease. However, the most dramatic change and the most important advantage we feel is, that today we have models to test a new hypothesis regarding the etiology of osteoporosis before it turns to dogma. Taken together, mouse-studies may lead to a shift in our physiological understanding of skeleton biology and to the emergence of novel paradigms. These, in turn, should help us to devise new treatments for degenerative diseases of the skeleton such as osteoporosis and its associated clinical problems.

[Animal Models for Bone and Joint Disease. Bone Disease of Osteoprotegerin Deficient Mouse].

Defective bone remodelling in osteoprotegerin-deficient mice.

Role of OPG/RANKL/RANK system during alveolar bone resorption and remodeling

Reduced Osteoblastic Population and Defective Mineralization in Osteopetrotic (op/op) Mice

High-Bone-Turnover Osteoporosis and Aortic Calcification in Opg Knockout Mice

Establishment of OPG Transgenic Mice and the Effect of OPG on Bone Microarchitecture

OPN, BSP, and Bone Quality—Structural, Biochemical, and Biomechanical Assessment in OPN−/−, BSP−/−, and DKO Mice

Immunolocalization of DMP1 and sclerostin in the epiphyseal trabecule and diaphyseal cortical bone of osteoprotegerin deficient mice.

Osteopenic mice: animal models of the aging skeleton.

Characterization of a spontaneous osteopetrosis model using RANKL-dysfunctional mice

OPG Knockout Mouse Teeth Display Reduced Alveolar Bone Mass and Hypermineralization in Enamel and Dentin

Oophorectomy‐induced Bone Loss is Attenuated in MAGP1‐deficient Mice

Osteoprotegerin deficiency attenuates strontium-mediated inhibition of osteoclastogenesis and bone resorption.

Changes of Bone Quality and Micro-Architecture in OPG-knockout Mice

Local Production of Osteoprotegerin by Osteoblasts Suppresses Bone Resorption

Osteocalcin and osteopontin influence bone morphology and mechanical properties

Novel Genetic Models of Osteoporosis by Overexpression of Human RANKL in Transgenic Mice

Chondrocytes-Specific Expression Of Osteoprotegerin Modulates Osteoclast Formation In Metaphyseal Bone

Effect of Anti‐TGF‐β Treatment in a Mouse Model of Severe Osteogenesis Imperfecta

Pleiotropic effects of a recessive C mutation occurring in a mouse model of severe osteogenesis imperfecta